News stories about Symmetry Medical (NYSE:SMA) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Symmetry Medical earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media headlines about the healthcare company an impact score of 44.8499888550107 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Symmetry Medical (SMA) Stock Price” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/17/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-symmetry-medical-sma-stock-price.html.

Symmetry Medical Company Profile

Symmetry Medical Inc (Symmetry) is a medical device solutions company, including surgical instruments, orthopedic implants, and sterilization cases and trays. The Company designs, develops and offers worldwide production and supply chain capabilities for these products to customers in the orthopedic industry, and other medical device markets (including but not limited to arthroscopy, dental, laparoscopy, osteobiologic, and endoscopy segments).

Insider Buying and Selling by Quarter for Symmetry Medical (NYSE:SMA)

Receive News & Ratings for Symmetry Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symmetry Medical and related companies with MarketBeat.com's FREE daily email newsletter.